Mark Deeg has been promoted to chief medical officer of Regulus Therapeutics (NASDAQ: [[ticker:RGLS]]), a San Diego-based biotech. Deeg joined Regulus in April as vice president of translational medicine. Before starting at Regulus, he was chief medical officer of The Chorus Group, an autonomous early drug development unit of Eli Lilly (NYSE: [[ticker:LLY]]).
Deeg’s promotion follows Regulus’ announcement Monday that it would halt development of its lead drug in hepatitis C, s well as a preclinical compound for cholestatic liver disease. Regulus also announced that drug partner AstraZeneca (NYSE: [[ticker:AZN]]) would stop work on a compound in early-stage clinical testing for the liver disease nonalcoholic steatohepatitis.
